[3] Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis sensitive to tulathromycin.

[3] Pigs: Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis, and Bordetella bronchiseptica sensitive to tulathromycin.

[3] Tulathromycin (brand name Draxxin) was approved for medical use in the European Union in November 2003.

[3] Tulathromycin (brand names Tulissin and Tulaven) was approved for medical use in the European Union in April 2020.

[9][10] In July 2020, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted positive opinions, recommending the granting of marketing authorizations for the veterinary medicinal products Increxxa and Tulinovet solutions for injection for cattle, pigs and sheep.